READ: Featured Drug Insights: March 2025 - Prime Therapeutics
READ: Featured Drug Insights: March 2025
Your source for all Prime Therapeutics' March 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for March 2025 will keep you informed on what’s trending now.
Released March 27, 2025
Clinical Highlights: March 2025
An overview of clinical insights’ trending topics and timely drug information highlights, this month covers how the United States (U.S.) Centers for Disease Control and Prevention (CDC) has been providing weekly updates on measles cases in the U.S.
Released March 26, 2025
A review of newly approved specialty drugs, recent drug launches and new indications in the last month, this month includes revakinagene taroretcel-lwey (Encelto), nilotinib d-tartrate (no trade name), denosumab-bmwo (Osenvelt) and more.
Released March 14, 2025
Expert Clinical Network Insights: March 2025
Committed to keeping you informed on the latest specialty drug insights from leading experts, this newsletter features remestemcel-L-rknd (Ryoncil).
Featuring commentary by Abby Kim, PharmD, BCOP on developments in the oncology space, this installment features a radiopharmaceutical discovery and how its use is gaining momentum.
FDA Decisions Expected for April 2025
A breakdown of FDA decisions expected of new drugs expected to hit the market. This edition covers Novavax COVID-19 vaccine, adjuvanted (NVX-CoV2373), reproxalap, elamipretide and more.
Providing a clinical deep dive into a select high cost drug in the pipeline. This month’s profile features Pegzilarginase Intravenous (IV), Subcutaneous (SC) | Immedica Metabolic and more.
Released March 4, 2025
A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are prademagene zamikeracel / (Abeona), brensocatib / Insmed, rebisufligene etisparvovec / (Ultragenyx) and more.
Looking for previous 2025 drug insights publications?
Simply click on the month to access past editions of our drug insights.
All brand names are property of their respective owners.